Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell- killing assay

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 10, 1996, Pages 2404-2409

  Boucher, Charles A B ^a,b   Keulen, Wilco ^a,b   Van Bommel, Toon ^a,b   Nijhuis, Monique ^a,b   De Jong, Dorien ^a,b   De Jong, Menno D ^b   Schipper, Pauline ^a,b   Back, Nicole K T ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; COMPLEMENTARY DNA; LAMIVUDINE; NEVIRAPINE; VIRUS ENZYME; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG SENSITIVITY; GENOTYPE; HELA CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS RECOMBINANT;

EID: 0029816733     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.10.2404     Document Type: Article

References (14)

1. Boom, R., C. J. A. Sol, M. M. M. Salimans, C. L. Jansen, P. M. E. Wertheimvan Dillen, and J. van der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
2. Brun-Vézinet, F., D. Ingrand, L. Deforges, K. Gochi, F. Ferchal, M.-P. Schmitt, M. Jung, B. Masquelier, J. Aubert, C. Buffet-Janvresse, and H. Fleury. 1992. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J. Virol. Methods 37:177-188.
3. de Jong, J. J., J. Goudsmit, W. Keulen, B. Klaver, W. Krone, M. Tersmette, and A. de Ronde. 1992. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J. Virol. 66:757-765.
4. de Jong, M. D., M. Loewenthal, C. A. Boucher, I. van der Ende, D. Hall, P. Schipper, A. Imrie, H. M. Weigel, R. H. Kauffmann, R. Koster, et al. 1994. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J. Infect. Dis. 169:1346-1350.
5. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, The RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
6. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
7. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
8. Larder, B. A., B. Chesebro, and D. D. Richman. 1990. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother. 34:436-441.
9. Nijhuis, M., C. A. B. Boucher, and R. Schuurman. 1995. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. BioTechniques 19:178-180.
10. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
11. Rocancourt, D., C. Bonnerot, H. Jouin, M. Emerman, and J. F. Nicolas. 1990. Activation of a β-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:2660-2668.
12. Schuurman, R., and W. Keulen. 1990. Modified protocol for DNA sequence analysis using Sequenase 2.0. BioTechniques 11:185.
13. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, et al. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
14. van Leeuwen, R., C. Katlama, V. Kitchen, C. A. Boucher, R. Tubiana, M. McBride, D. Ingrand, J. Weber, A. Hill, H. McDade, et al. 1995. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171:1166-1171.